Compare Bristol-Myers Squibb Co (BMY) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Wendys Co — how do they compare? Bristol-Myers Squibb Co trades at $63.97 (market cap $129.94B), while Wendys Co trades at $8.54 (market cap $1.44B). The key difference: Bristol-Myers Squibb Co is far larger — about 90.2× Wendys Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | WEN | |
|---|---|---|
Market Cap | $129.94B | $1.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $65.89 | $10.68 |
52-Week Low | $42.60 | $6.17 |
Enterprise Value | $163.92B | $5.17B |
Dividend Yield | 3.96% | 3.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
WEN trades at $8.595, up 17.74% in 24 hours, with a neutral technical signal. Recent Q2 2026 EPS of $0.18 beat expectations, but revenue trends are flat and net income margin declined to 5.72% in 2025. The company cut its dividend and withdrew 2026 guidance amid a strategic turnaround under new leadership, facing traffic declines and loss of its No. 2 U.S. burger chain position to Burger King.
Outlook is cautious; the dividend cut frees cash for restructuring, but execution risks are high. Valuation appears reasonable with a P/E of 11.44, though high debt and competitive pressures pose significant headwinds. Analyst consensus is mixed, with 62.75% hold ratings reflecting uncertainty around the turnaround plan's success.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
